Intravacc Awarded US$14.6 Million NIH/NIAID Contract to Develop Intranasal Gonorrhea Vaccine R&D, Therapeutics Intravacc will develop a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology. Read more October 5, 2022/by Administrator https://www.pharmalive.com/wp-content/uploads/2022/10/Intravacc.jpg 500 767 Administrator https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Administrator2022-10-05 02:00:252022-10-05 09:55:50Intravacc Awarded US$14.6 Million NIH/NIAID Contract to Develop Intranasal Gonorrhea Vaccine
